Jon C

[Jon C @JonCOrtho]

$MSLE At this valuation, the risk to reward on any upcoming data readouts for their basecamp and trailhead studies is a 5-10x. I’m adding to my position once again.

[Jon C @JonCOrtho]

@obryanjf When do you think they will give an update on the number of individuals dosed? It seems like the goal is July, if they want to have top line data by 4th quarter.

[Jon C @JonCOrtho]

@Jaro_rogue Excited to see where life takes you next! 👊

[Jon C @JonCOrtho]

@unusual_whales So…. Like $70 will stay in Canada instead of $20.

[Jon C @JonCOrtho]

@bingbingbom @boridn32862 ?

[Jon C @JonCOrtho]

@FidelisAurelius Largest volume day since joining the Nasdaq. Someone bought a truckload today. I think it is a great entry. I'm still holding long term.

[Jon C @JonCOrtho]

Exactly what I was hoping they would announce. The bar is so low clinically to show success. If the most challenging group, non ambulatory DMD patients, show even the slightest continual improvement or stability, the entire stock is derisked significantly for a long term hold with the possible 10-20x increase.

[Jon C @JonCOrtho]

$MSLE If their presentation today is positive, like this announcement, $MSLE should rerate to at least $1B market cap and be trading $20+ in short order. Benefits starting to show in non ambulatory DMD patients and serviceable market potentially increasing significantly with FSHD. I’ll add if we open below $14. 👊

[Satellos Bioscience @SatellosBio]

$MSLE News: Today, we announced interim clinical and biomarker data for SAT-3247 at the @MDAorg Clinical & Scientific Conference in Orlando, Florida.

Full details in our press release: https://t.co/soyHrCvFV6

#MDAConference #MDA2026 #MuscleRegeneration #Duchenne $MSCL

[Jon C @JonCOrtho]

@SatellosBio @MDAorg Initial thoughts are this looks extremely promising plus may be beneficial in FSHD. Excited to see the ongoing Data today. Nice work Satellos BS! $MSLE

[Jon C @JonCOrtho]

@SatellosBio @MDAorg Excited for your next data release!

[Jon C @JonCOrtho]

@FidelisAurelius @anish_koka Completely agree. The bar needs to be much higher clinically to approve many of these treatments.

[Jon C @JonCOrtho]

@FidelisAurelius If true, every DMD patient will want to be on $MSLE oral ASAP.

[Jon C @JonCOrtho]

@FidelisAurelius It’s my largest position by far! 🤞 It’s time to share some data. Hopefully next week.

[Jon C @JonCOrtho]

@charle77238 I literally did the same trade this morning....$ABVX

[Jon C @JonCOrtho]

@charle77238 Just getting started.....

[Jon C @JonCOrtho]

@bingbingbom Walmart seems like a pretty solid short ad this point. 😂 $WMT

[Jon C @JonCOrtho]

@FidelisAurelius Disease reversal valuation multiplies to $5B+. If it expands to other types of MD…$10B+. Price would be $200-$400 a share. I would likely retire. 😂

Obviously beyond the money, it would be forever life changing for those families and individuals dealing with MD

[Jon C @JonCOrtho]

@FidelisAurelius If there is evidence of disease reversal or stagnation… I don’t see how $MSLE trades less than $100, $2.5B valuation.